Absorption of Covidshield Technologies into Biocon Biologics

0
1352
Competition Corporation India
Competition Corporetion India
0 0
Azadi Ka Amrit Mahoutsav

InterServer Web Hosting and VPS
Read Time:1 Minute, 25 Second

CCI approves merger by absorption of Covidshield Technologies into Biocon Biologics in consideration for the acquisition of approximately 15% equity shareholding of Biocon Biologics by Serum Institute Life Sciences

By PIB Delhi

The Competition Commission of India (CCI) approves the merger by absorption of Covidshield Technologies into Biocon Biologics in consideration for the acquisition of approximately 15% equity shareholding of Biocon Biologics by Serum Institute Life Sciences

The Proposed Combination involves a merger by absorption of Covidshield Technologies Private Limited (CTPL), a wholly-owned subsidiary of the Serum Institute Life Sciences Private Limited (Acquirer) into the Biocon Biologics Limited (Target) pursuant to a scheme of the merger in consideration of which the Acquirer will acquire approximately 15% equity shareholding on a fully diluted basis in the Target.

The Acquirer is a subsidiary of Serum Institute of India Private Limited and was established as a company for the further development and commercialization of vaccines and therapies against COVID-19. It also had plans to further develop vaccines against other infectious diseases. At present, the Acquirer is in the process of setting up its own manufacturing facility.

CTPL is a wholly-owned subsidiary of the Acquirer, which shall be merged into the Target pursuant to the Proposed Transaction. It was incorporated to undertake the business of marketing, selling, and distributing vaccines, drugs, and other pharmaceutical products.

The Target is a subsidiary of Biocon Limited, and it offers treatment for chronic and acute diseases such as diabetes, oncology, nephrology, cancer, and autoimmune diseases. Target also has research and development centres in Bengaluru and Chennai. It has manufacturing facilities in Bengaluru and Malaysia for monoclonal antibodies, recombinant proteins, and insulins.

Detailed order of the CCI will follow.

About Post Author

Editor Desk

Antara Tripathy M.Sc., B.Ed. by qualification and bring 15 years of media reporting experience.. Coverred many illustarted events like, G20, ICC,MCCI,British High Commission, Bangladesh etc. She took over from the founder Editor of IBG NEWS Suman Munshi (15/Mar/2012- 09/Aug/2018 and October 2020 to 13 June 2023).
Happy
Happy
0 %
Sad
Sad
0 %
Excited
Excited
0 %
Sleepy
Sleepy
0 %
Angry
Angry
0 %
Surprise
Surprise
0 %
Advertisements

USD





LEAVE A REPLY

Please enter your comment!
Please enter your name here